Bleeding News and Research

RSS

Cancer drug could be effective for treating recurrent nose bleeds

Patients suffering from hereditary hemorrhagic telangiectasia (HHT), an inherited vascular condition characterized by profuse nosebleeds, may find hope in a cancer-fighting drug called bevacizumab, also known as Avastin.

12 Feb 2010

Study may pave for effective treatments for blood clotting disorders

A key protein that causes the blood to clot is produced by blood vessels in the lungs and not just the liver, according to new research published today in the journal PLoS One, led by scientists at Imperial College London.

11 Feb 2010

Glide Pharma to utilize $4.3M funding for progressing octreotide programme into clinical development

Glide Pharma, a specialty pharmaceutical company focused on the needle-free administration of solid dose therapeutics and vaccines, today announced that it has completed an oversubscribed GBP2.7 million ($4.3 million) investment round. The fundraising was supported by a number of existing institutional and private investors, including Hygea VCT and Oxford Technology VCTs. The company has now completed four successful investment rounds, securing funding totalling approximately GBP10 million.

10 Feb 2010

Researchers find that mutation in single gene can cause endometrial cancer

A mutation in a single gene can cause endometrial cancer that is responsive to a specific drug therapy, researchers at UT Southwestern Medical Center have found in an animal study.

10 Feb 2010

Excelsior Medical receives Canadian marketing license for new, pre-filled catheter lock syringe

Excelsior Medical Corporation, one of the leading manufacturers of pre-filled catheter flush syringes, today announced that it has received a Medical Device License from Health Canada for its new, pre-filled catheter lock syringe to be sold in the Canadian marketplace.

10 Feb 2010

Journal highlights toxic nature of herbal medicines

A University of Adelaide forensic pathologist has sounded a worldwide warning of the potential lethal dangers of herbal medicines if taken in large quantities, injected, or combined with prescription drugs.

9 Feb 2010

Positive data from Cara Therapeutics' peripherally-restricted kappa opioid agonist Phase II trial

Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845. The 46 patient Phase II, multi-center, double-blind, placebo-controlled study was conducted at eight hospitals in the United States and evaluated the efficacy and safety of CR845 in women following laparoscopic-assisted hysterectomy.

9 Feb 2010

Gene linked to endometrial cancer identified

Endometrial cancer is the most common cancer of the female reproductive tract, representing 6% of all cancers. There is currently no screening method or biomarker to indicate early presence of disease. "It is a very common malignancy that affects women of all ages" comments paper author Dr. Diego Castrillon. The cancer forms from the cells that grow along the inner lining of the uterus, which is called the endometrium, and usually it is diagnosed following patient reports of abnormal bleeding.

8 Feb 2010

Oral care with ionic toothbrush

Smile and the world smiles with you. Well, the folks at Global Ionics LLC, makers of the Ionic ProClean toothbrush, are smiling a lot these days; especially since receiving the impressive results of a clinical evaluation conducted by THE DENTAL ADVISOR. In a clinical assessment, the Ionic ProClean was evaluated by a team of dental professionals and 107 patients in over 11,100 uses. The results? Dental professionals reported that they observed less tartar buildup and gingivitis, and believed the toothbrush contributed to good oral hygiene: earning the Ionic ProClean a 4+ rating from THE DENTAL ADVISOR.

6 Feb 2010

NHLBI awarded four contracts to test new devices to help children with congenital heart defects

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, has awarded four contracts totaling $23.6 million to begin preclinical testing of devices to help children born with congenital heart defects or those who develop heart failure.

5 Feb 2010

Polymedco's automated immunoassay fecal occult blood test system receives FDA clearance

Polymedco, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the OC-Sensor Diana, a high throughput automated system for the immunoassay fecal occult blood test (FIT) used for detecting gastrointestinal bleeding associated with disorders such as colorectal cancer, polyps and colitis.

5 Feb 2010

Daiichi Sankyo initiates Phase III trial of edoxaban in reducing recurrent VTE complications

Daiichi Sankyo Company, Limited, announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI (pronounced hoe·koo·sigh) VTE, is evaluating the safety and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) complications in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE).

3 Feb 2010

Xiaflex receives FDA approval for treatment of Dupuytren's contracture

The U.S. Food and Drug Administration today approved Xiaflex (collagenase clostridium histolyticum) as the first drug to treat a progressive hand disease known as Dupuytren's contracture, which can affect a person's ability to straighten and properly use their fingers.

2 Feb 2010

Halt Medical commences enrollment in uterine fibroid study

The Wall Street Journal, CBS, and other popular news outlets have recently featured headline stories about a clinical study that is recruiting patients suffering with uterine fibroids. "We're not at all surprised by the attention this study is getting from the media," said Russ DeLonzor, President and Chief Operating Officer of Halt Medical, Inc., a medical technology company headquartered near San Francisco.

2 Feb 2010

Cardiac catheterization: A groundbreaking tool in the field of cardiology

Cardiac catheterizations have been a groundbreaking tool in the field of cardiology. This procedure offers a minimally invasive means for obtaining important information about the heart and its blood vessels, while also providing a less invasive treatment for certain heart conditions.

2 Feb 2010

Serious liver disorder associated with use of HIV drug, FDA warns

The U.S. Food and Drug Administration today announced that non-cirrhotic portal hypertension, a rare, but serious, liver disorder, has been reported in some HIV patients taking Videx/Videx EC (didanosine).

2 Feb 2010

Ipsen reports consolidated group sales of €1,032.8M for 2009

Ipsen reported today its sales for the fourth quarter and full year 2009.

1 Feb 2010

Salient Surgical Technologies, Exeter Hospital and Moffitt Cancer Center donate medical supplies to Haiti

Salient Surgical Technologies of Portsmouth, New Hampshire, has partnered with Exeter Hospital in Exeter, New Hampshire and Moffitt Cancer Center in Tampa, Florida, to donate equipment and supplies for a mission to aid victims of the January 12 earthquake in Haiti.

30 Jan 2010

Access Scientific's PICC WAND receives FDA clearance

Access Scientific has received FDA clearance for The PICC WANDTM, which enables clinicians to insert a peelable sheath for PICC or Midline catheter placement using the new Accelerated Seldinger Technique (AST). The PICC WAND is an all-in-one safety introducer that addresses the over-wire vascular access market, valued at more than $1 billion, by providing faster, safer and simpler vascular access.

27 Jan 2010

Discovery challenges understanding of blood cell development

University of Utah researchers led an international team of scientists that is the first to report on the previously undescribed ability of platelets to reproduce themselves in the circulation. Their revolutionary findings were published online Jan. 19, 2010, in the journal Blood.

27 Jan 2010